RESEARCH PAPER

Artificial Intelligence in Diabetes: A Systematic Review of its Role in Early Diagnosis, Treatment Optimization, and Disease Management

Priyanka Viswanath[1*], Dr. Prerna Tejaswi[2]

[1*]2nd year MBBS student, Department of Pharmacology, Rajarajeswari Medical College & Hospital, Bengaluru, Dr.M.G.R Educational and Research Institute (University), priyankaviswanath007@gmail.com
[2]Assistant Professor, Department of Pharmacology. Rajarajeswari Medical College & Hospital, Bengaluru, Dr.M.G.R Educational and Research Institute (University),
Corresponding author: Dr. Prerna Tejaswi, prernatejaswi@yahoo.in

Abstract: -
Introduction: Diabetes is a widespread lifestyle disease requiring early diagnosis and regular monitoring to prevent complications. Traditional methods may miss early warning signs or depend heavily on patient compliance. Artificial Intelligence (AI) offers tools that can predict risk, support diagnosis, and guide daily management. This review surveys current applications of AI in diabetes care.
Objectives: To assess the role of AI in the early detection of diabetes, treatment decisions and improves blood sugar control and manage diabetes in daily life, including apps and monitoring systems.
Methodology:
This review conducted a systematic search of published studies on AI use in diabetes care. Databases including PubMed, Google Scholar, and Scopus were searched using terms such as "AI," "machine learning," and "diabetes." English-language articles focusing on diagnosis, prediction, or management were included. Titles and abstracts were screened, followed by full text evaluation. Duplicate and unrelated studies were excluded. Key findings were extracted and categorized into themes, early detection, treatment support, and long term management.
Results: Synthesis of 17 peer-reviewed studies identified three primary domains of impact. In Domain I (Diagnosis), machine learning models achieved Area Under the Curve (AUC) values >0.75 for early risk prediction, while deep learning (CNNs) reached specialist level diagnostic sensitivities of 90.5%–91% globally and up to 95.8% in Indian smartphone based cohorts (AUC 0.94–0.99). In Domain II (Treatment), Hybrid Closed-Loop systems significantly increased Time in Range (TIR) by an average of 11% (approx. 2.6 hours/day) and enhanced glycemic stability via predictive titration algorithms. In Domain III (Management), AI-enabled digital companions and decision support platforms improved monitoring consistency, provided real time emergency alerts for glycemic excursions, and reduced the cognitive burden of self-management through multi modal data fusion.
Conclusion:
AI demonstrates strong potential to enhance early diagnosis, improve treatment decision making, and support ongoing self-management in diabetes care. Predictive algorithms, automated image based screening, and intelligent monitoring tools reduce diagnostic delays and support more stable glycaemic control. However, wider validation and real world implementation studies are needed before large scale clinical adoption.

Keywords: Artificial Intelligence; Diabetes mellitus; Machine learning; Diagnosis; Management; Digital health; Predictive modelling.

How to cite this article: Viswanath P, Tejaswi P. Artificial Intelligence in Diabetes: A Systematic Review of its Role in Early Diagnosis, Treatment Optimization, and Disease Management. Int J Drug Deliv Technol. 2026;16(4s): 111-116. DOI: 10.25258/ijddt.16.4s.14

Conflict of interest: None

INTRODUCTION

Diabetes mellitus has transitioned from a manageable lifestyle condition into a global public health crisis of unprecedented scale. As of 2026, the global burden aligns with the sobering projections of the International Diabetes Federation (IDF), which estimates that over 580 million adults are currently living with the disease **[1]**. This crisis is nowhere more evident than in India. Once considered a "fancy" disease of the affluent, diabetes has become a pervasive comorbidity across the Indian population, leading many to label the nation as the "Diabetes Capital of the World."

The rationale for this escalating risk in India is multi faceted. Urbanization has led to a significant shift in lifestyle, where the traditional carbohydrate heavy and fat rich diet remains a cultural staple, yet the physical exertion of rural life has been replaced by sedentary urban routines. This "mismatch" between high caloric intake and low physical output has created a perfect storm for metabolic dysfunction. Furthermore, the asymptomatic nature of early stage diabetes means that millions of individuals remain undiagnosed until microvascular or macrovascular complications such as retinopathy or cardiovascular disease become irreversible **[2]**.

*Author for Correspondence: prernatejaswi@yahoo.in

Traditional clinical approaches, which rely on periodic finger prick tests and patient compliance, are increasingly viewed as insufficient for capturing the volatile nature of daily glycemic excursions. There is a critical need to move beyond "snapshot" medicine toward a continuous, data driven model of care.

Artificial Intelligence (AI) has emerged as the most viable technology to bridge this gap. By leveraging machine learning (ML) and deep learning (DL), AI can process massive volumes of patient data to predict risks before they manifest clinically **[3, 4]**. While the popularity of AI is growing globally, there is an urgent need for a synthesized review that provides a "final picture" of how this tool can be practically established in healthcare. This review aims to evaluate AI's role in transforming diabetes from a poorly managed chronic burden into a precisely controlled condition through advanced diagnosis, treatment, and long-term monitoring.

MATERIALS AND METHODS

This systematic review was conducted to evaluate the applications of Artificial Intelligence (AI) in diabetes care. The review process was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement **[5]**.

A comprehensive literature search was performed using PubMed, Google Scholar, and Scopus databases and a total of 17 studies [6-22] were selected. Search terms included combinations of Artificial intelligence, diabetes mellitus, machine learning, diagnosis, management, digital health, and predictive modelling. Only English language, peer reviewed original research articles and routine clinical trials published in indexed journals were considered.

Eligibility Criteria: The selection of studies for this review was further refined using the PICO (Population, Intervention, Comparison, and Outcome) framework.

Population: Patients diagnosed with Type 1 or Type 2 Diabetes Mellitus, with a focus on high burden urban populations and those with metabolic syndrome.

Intervention: Healthcare models or clinical tools utilizing Artificial Intelligence (AI), Machine Learning (ML), or Deep Learning (DL) architectures.

Comparison: Conventional standard of care, including manual insulin titration, human graded diagnostic screenings, and traditional glucose monitoring.

Outcomes: Quantitative performance metrics such as Area Under the Curve (AUC), Sensitivity, Specificity, Time in Range (TIR), and glycated hemoglobin (HbA1c) reduction.

Selection and Data Collection Process: The selection process involved a two-stage screening: an initial evaluation of titles and abstracts for relevance, followed by a rigorous full text assessment against the inclusion criteria. Data extraction was conducted using a standardized template to record study design, AI architecture (e.g., Convolutional Neural Networks), and primary clinical findings. For the purpose of synthesis, studies were categorized into three functional domains:

Diagnosis: Automated screening and early risk stratification.

Treatment: Algorithmic insulin optimization and closed loop delivery systems.

Management: Decision support tools and AI driven remote monitoring.

RESULTS

A total of 17 studies were included in this systematic review. These studies evaluate the efficacy of Artificial Intelligence (AI) across the entire spectrum of diabetic care. The synthesized evidence was categorized into three distinct thematic domains: (I) Diagnosis and Early Risk Prediction, (II) Treatment Optimization, and (III) Long-term Daily Management.

Domain I: Diagnosis and Early Risk Prediction

AI-Driven Risk Prediction and Stratification: In the sphere of early identification, machine learning models demonstrate high clinical efficacy in identifying patterns associated with the risk of a person progressing to clinical Diabetes Mellitus. By processing routine clinical data, including Body Mass Index (BMI), waist to hip ratio, lipid profiles, and longitudinal HbA1c levels. These models can recognize subtle metabolic shifts that traditional risk scores may overlook.

The synthesized evidence suggests that integrating physical fitness metrics and activity levels further enhances the predictive accuracy of these algorithms. These models act as a "clinical early warning system," allowing for the recognition of pre diabetics and the implementation of interventions as early as possible. This proactive approach is essential to prevent the pre diabetic population from being diagnosed with full onset diabetes mellitus. Validation data consistently reported Area Under the Curve (AUC) values exceeding 0.75, confirming the utility of these simple models in identifying at risk individuals using data already available in standard clinical settings.

Clinical Diagnosis of Microvascular Complications: Beyond risk stratification, deep learning architectures, specifically Convolutional Neural Networks (CNNs), have achieved specialist level accuracy in diagnosing diabetic retinopathy (DR). These systems utilize automated image analysis to localize microaneurysms, hemorrhages, and exudates within retinal fundus photographs.

In large scale validation efforts, these models demonstrated high diagnostic performance across both international and Indian populations. International pivotal trials reported sensitivities of 90.5% to 91%, while studies specifically targeting Indian cohorts using smartphone based fundus photography reported sensitivities as high as 95.8%. The high AUC (ranging from 0.94 to 0.99) across these studies confirms that AI can effectively reduce the diagnostic workload on ophthalmologists and enable mass population screening in underserved regions where specialist access is limited.



Table 1: Synthesis of Original Research in Domain I

Sub-Domain	Input Parameters	Primary AI Technique	Key Clinical Metric
Risk Prediction	BMI, HbA1c, Lipids, Waist-Hip Ratio, Fitness	Machine Learning (ML)	**AUC > 0.75**
Diagnosis (Global)	Retinal Fundus Photographs	Deep Learning (CNN)	**Sens: 90.5–91%**
Diagnosis (India)	Smartphone-based Fundus Photos	Deep Learning (CNN)	**Sens: 95.8%**
Feature Detection	Hybrid Imaging Data	Explainable AI (XAI)	**AUC: 0.94–0.99**

Domain II: Treatment Optimization and Glycemic Control

Automated Insulin Delivery and the Artificial Pancreas

In the management of Type 1 and advanced Type 2 Diabetes, original clinical trials have validated the efficacy of Hybrid Closed-Loop (HCL) systems, commonly referred to as the "Artificial Pancreas." These systems integrate Continuous Glucose Monitoring (CGM) with insulin pump therapy via advanced control algorithms. The synthesized data from multi month trials indicates that these systems significantly increase the Time-in-Range (TIR) the percentage of time blood glucose remains within the target window of 70–180 mg/dL.

Clinical outcomes show an average TIR increase of over 11%, which equates to approximately 2.6 additional hours per day of euglycemia. Furthermore, these automated systems demonstrate a superior ability to reduce nocturnal hypoglycemia compared to conventional sensor augmented pump therapy, providing a safer profile for long term glycemic stability.

Personalization and Patient Compliance

The treatment of metabolic diseases like Diabetes Mellitus is a life-long entity. In this aspect, AI allows the patient to personalize their treatment according to their schedule or preferences, which significantly increases patient compliance. By utilizing Model Predictive Control (MPC) and fuzzy logic algorithms, insulin delivery is no longer a static "one-size-fits-all" calculation. Instead, the AI adapts to real world variables such as exercise, stress, and missed boluses. This transition from manual management to "digital copiloting" reduces the mental burden of the disease, allowing patients to maintain tighter control without the constant requirement for manual calculations.

Novel Drug Delivery and Decision Support

AI driven decision-support systems have also been validated for patients on Multiple Daily Injections (MDI). These tools analyze past glycemic responses to suggest optimal insulin dosages for meals and basal corrections. Original trials have found a high degree of correlation between AI recommendations and expert physician advice, suggesting that AI can provide specialist level titration guidance in a home setting. This ensures that drug delivery is optimized to the patient's specific insulin sensitivity, further reducing the risk of long-term complications.

Table 2: Original Research Findings in AI-Driven Treatment

Application	AI Technique	Primary Clinical Outcome	Performance Metric
Artificial Pancreas	Model Predictive Control	Increased Time-in-Range (TIR)	**TIR Increase > 11%**
Nocturnal Safety	Closed-Loop Algorithms	Reduction in Sleep Hypoglycemia	**Fewer low-glucose events**
Personalized Care	Adaptive Algorithms	Increased Patient Compliance	**Reduced User Intervention**
MDI Support	Predictive Analytics	HbA1c Reduction	**Clinically Significant Improvement**

Domain III: Long-term Management and Digital Health Support

AI as a Digital Companion for Chronic Care

The management of Diabetes Mellitus can be a heinous task, especially in newer patients and those with Type I Diabetes. These individuals are under a significant risk of developing life threatening complications such as hypoglycemia or diabetic ketoacidosis (DKA) if not monitored properly. The burden is particularly high for patients with no constant helpers or family members to look after and monitor their health. In this context, AI tools serve as a critical lifesaver by bridging the gap between periodic clinical consultations and the constant 24/7 reality of living with a chronic condition.

Predictive Support and Emergency Alerts

Original clinical evaluations of decision-support platforms have demonstrated the ability of AI to analyze Continuous Glucose Monitoring (CGM) data to predict hyperglycemic and hypoglycemic events before they manifest clinically. These platforms can automate the monitoring process, providing real-time alerts that can be shared with designated emergency contacts or healthcare providers when a dangerous drop in glucose is detected. By integrating lifestyle data including dietary intake, physical activity, and sleep patterns, these ecosystems provide personalized feedback that fosters necessary behavioral changes.

Holistic Management and Automated Reminders

Advanced AI enabled platforms have also begun to integrate data from comorbid conditions, such as hypertension and dyslipidemia, facilitating a holistic approach to chronic disease management. Pilot trials indicate that these integrated platforms significantly improve monitoring consistency and patient engagement. By automating insulin reminders and synchronizing with delivery systems like the artificial pancreas, AI reduces the cognitive load on the patient, ensuring that insulin administration is timely and accurate even in the absence of a dedicated caregiver.

Table 3: Original Research Findings in Long-term Management

Application	AI Technique	Key Features	Clinical Impact
Decision Support	Predictive Analytics	Real-time CGM trend analysis	Early prediction of glycemic excursions
Emergency Safety	Automated Alert Systems	Hypoglycemia alerts to contacts	Prevention of severe hypoglycemic coma
mHealth Integration	Adaptive Algorithms	Diet, sleep, and activity tracking	Improved adherence and behavioral change
Comprehensive Care	Multi-modal Data Fusion	Comorbidity tracking (BP/Lipids)	Holistic management of metabolic healt

DISCUSSION

The findings of this research illustrate a fundamental shift in diabetes care, where Artificial Intelligence (AI) has transitioned from an experimental interest to a clinically validated necessity. The results indicate that AI has established itself as a clinical early warning system, utilizing routine data like BMI and lipid profiles to identify pre diabetic shifts that traditional scores frequently overlook. This predictive power is matched by diagnostic precision, where deep learning architectures have achieved accuracy in detecting complications such as diabetic retinopathy using retinal fundoscopy images at the earliest. Beyond the diagnostic stage, the implementation of "Artificial Pancreas" systems has fundamentally altered the treatment landscape, gifting patients significant additional hours of euglycemia daily. Most importantly, in the long term management of this life long condition, AI emerges as a digital companion, providing a critical safety net through automated alerts and personalized feedback that fosters sustained patient compliance. Overall, AI has emerged as a tool that helps patients personalize their treatment regimen.

In the context of current literature, our findings regarding diagnostic accuracy are in strong concurrence with a landmark meta-analysis by Liu et al. [23], which established that deep learning algorithms achieve diagnostic performance equivalent to healthcare professionals when using medical imaging. This is further supported by recent 2025-2026 evidence from Ullah et al. [24], whose systematic review confirmed that AI driven diagnostic technologies effectively evaluate medical images, regularly identifying details overlooked by the human eye and leading to more rapid diagnoses. These parallels reinforce the narrative that AI's primary value lies in its ability to process high dimensional data at a speed and consistency that supports clinical decision making.

However, certain aspects of our review do not fully align with the broader challenges identified in earlier seminal works. While Kelly et al. [25] highlighted significant barriers regarding the "black box" nature of algorithms and a lack of prospective validation, our findings indicate a more optimistic trend.

The primary strength of this work is its focus on the clinical utility of automated systems in diverse settings. By highlighting how these tools perform,not just in controlled trials but in smartphone based screenings and routine metabolic tracking, the research proves that high-level diagnostics are becoming accessible outside of tertiary centers. The ability to identify early metabolic shifts with high precision provides a proactive "safety net" that traditional, periodic checkups often miss.

However, the shift toward automation is not without friction. A significant limitation remains the "interpretability gap." While a model may provide a highly accurate risk score, the lack of a transparent clinical rationale can lead to hesitation in a high stakes medical environment. Furthermore, these systems are highly dependent on the quality of input data; in a busy clinic, factors like suboptimal imaging or inconsistent patient data entry can compromise the results. We must also remain cautious of the "digital divide," ensuring these advancements do not inadvertently widen the gap for patients without consistent access to hardware or stable connectivity.

For the practicing physician, these findings signal a transition from manual data oversight to high level interpretation. By delegating the constant monitoring of glucose trends or the initial grading of retinal images to reliable systems, the clinician is no longer a data processor. This shift allows the provider to focus on the elements of medicine that require human judgment: complex ethical decisions, nuanced counseling, and the empathetic management of a life long illness.

Future research must move beyond simply measuring accuracy in a vacuum. The next milestone is "prospective validation" proving that these systems lead to better long term outcomes, such as reduced complication rates over a decade, rather than just improved metrics over a few months. There is also a critical need for "explainable" frameworks that allow a consultant to verify the logic behind a system’s recommendation, turning a closed system into a collaborative tool.

CONCLUSION:

The evidence synthesized in this systematic review underscores a pivotal shift in the management of metabolic disease: Artificial Intelligence has evolved from an experimental curiosity into an essential anchoring force in diabetes care. However, it is imperative to clarify that AI is fundamentally a sophisticated clinical tool, not a virtual doctor. Its value does not lie in replacing the nuanced judgment, empathy, and holistic understanding of a human physician, but in its unparalleled ability to process vast datasets with speed and precision that exceed human capacity.

By drastically decreasing the time required for diagnosing sight threatening complications and analyzing complex glycemic patterns, AI bridges the gap between the staggering volume of patient data and the limited time of medical specialists. In high burden regions like India, this "efficiency gain" is not a mere convenience; it is the difference between early intervention and irreversible disability.

Ultimately, the role of AI is to handle the computational load from the automated classification of retinal lesions to the micro adjustment of insulin doses thereby freeing the clinician to focus on the human complexities of the patient-provider relationship. As we move forward, the integration of these technologies should be viewed through the lens of augmented intelligence, where the machine provides the data driven insights and the doctor provides the wisdom. This collaborative model is the most viable path toward curbing the global diabetes epidemic and improving the long term survival and quality of life for millions of patients worldwide.

REFERENCES:

1. Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. *IDF Diabetes Atlas*. 10th ed. Brussels: International Diabetes Federation; 2021.
2. Zheng T, Xie W, Xu L, et al. EHR-based framework for identifying patients with type 2 diabetes mellitus. *J Med Syst*. 2017;41(8):127.

3. Kavakiotis I, Tsave O, Salifoglou A, Maglaveras N, Vlahavas I, Chouvarda I. Machine Learning and Data Mining Methods in Diabetes Research. *Comput Struct Biotechnol J*. 2017;15:104-116.
4. Zou Q, Qu K, Luo Y, Yin D, Ju Y, Tang H. Predicting Diabetes Mellitus with Machine Learning Techniques. *Front Genet*. 2018;9:515.
5. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71
6. Gulshan V, Peng L, Coram M, et al. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA. 2016;316(22):2402–2410. doi:10.1001/jama.2016.17216
7. Ting DSW, Cheung CY, Lim G, et al. Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes. JAMA. 2017;318(22):2211–2223. doi:10.1001/jama.2017.18152
8. Rajalakshmi, R., Subashini, R., Anjana, R.M. *et al.* Automated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligence. *Eye* 32, 1138–1144 (2018). https://doi.org/10.1038/s41433-018-0064-9
9. Abràmoff, M.D., Lavin, P.T., Birch, M. *et al.* Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. *npj Digital Med* 1, 39 (2018). https://doi.org/10.1038/s41746-018-0040-6
10. Sayres R, Taly A, Rahimy E .Using a Deep Learning Algorithm and Integrated Gradients Explanation to Assist Grading for Diabetic Retinopathy Ophthalmology, 2018; 126, 552-564
11. Zou Q, Qu K, Luo Y, Yin D, Ju Y and Tang H (2018) Predicting Diabetes Mellitus With Machine Learning Techniques. Front. Genet. 9:515. doi: 10.3389/fgene.2018.00515
12. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. *N Engl J Med*. 2019;381(18):1707-1717. doi:10.1056/NEJMoa1907863
13. Tauschmann M, Thabit H, Bally L et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial The Lancet, 2018; 392, 1321-1329
14. Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA. 2016;316(13):1407–1408. doi:10.1001/jama.2016.11708
15. Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, Brown SA, Chernavvsky DR, Breton MD, Mize LB, Farret A, Place J, Bruttomesso D, Del Favero S, Boscari F, Galasso S, Avogaro A, Magni L, Di Palma F, Toffanin C, Messori M, Dassau E, Doyle FJ 3rd. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care. 2014 Jul;37(7):1789-96. doi: 10.2337/dc13-2076. Epub 2014 Jun 14. PMID: 24929429; PMCID: PMC4067397.
16. Haidar A, Tsoukas MA, Bernier-Twardy S, Yale JF, Rutkowski J, Bossy A, et al. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial. *Diabetes Care*. 2020;43(3):597–606. doi:10.2337/dc19-1922
17. Nimri R, Oron T, Muller I, Kraljevic I, Alonso MM, Keskinen P, Milicic T, Oren A, Christoforidis A, den Brinker M, Bozzetto L, Bolla AM, Krcma M, Rabini RA, Tabba S, Smith L, Vazeou A, Maltoni G, Giani E, Atlas E, Phillip M. Adjustment of Insulin Pump Settings in Type 1 Diabetes Management: Advisor Pro Device Compared to Physicians' Recommendations. J Diabetes Sci Technol. 2022 Mar;16(2):364-372. doi: 10.1177/1932296820965561. Epub 2020 Oct 26. PMID: 33100030; PMCID: PMC8861776.
18. Bent B, Cho PJ, Wittmann A, et al. De novo prediction of fasting glucose from continuous glucose monitor data using deep learning. Lancet Digit Health. 2020;2(11):e603-e613. doi:10.1016/S2589-7500(20)30225-4
19. Miller EM. Using Continuous Glucose Monitoring in Clinical Practice. Clin Diabetes. 2020 Dec;38(5):429-438. doi: 10.2337/cd20-0043. PMID: 33384468; PMCID: PMC7755046.
20. Datye KA, Boyle CT, Simmons J, Moore DJ, Jaser SS, Sheanon N, Kittelsrud JM, Woerner SE, Miller KM; T1D Exchange. Timing of Meal Insulin and Its Relation to Adherence to Therapy in Type 1 Diabetes. J Diabetes Sci Technol. 2018 Mar;12(2):349-355. doi: 10.1177/1932296817728525. Epub 2017 Sep 12. PMID: 28895431; PMCID: PMC5851213.
21. Muthukumar P, Srinivasan S, Ramkumar G, Kannan S, Balas VE. Enhanced explainable deep learning model for diabetic retinopathy classification and localization. *Sci Rep*. 2023;13(1):11211. doi:10.1038/s41598-023-38243-w
22. Cappon G, Vettoretti M, Sparacino G, Facchinetti A. Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications. *Diabetes Metab J*. 2019;43(4):383-397. doi:10.4093/dmj.2019.0121
23. Liu X, Faes L, Kale AU, Wagner SK, Fu DJ, Bruynseels A, Mahendiran T, Moraes G, Shamdas M, Kern C, Ledsam JR, Schmid MK, Balaskas K, Topol EJ, Bachmann LM, Keane PA, Denniston AK. A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. Lancet Digit Health. 2019 Oct;1(6):e271-e297. doi: 10.1016/S2589-7500(19)30123-2. Epub 2019 Sep 25. Erratum in: Lancet Digit Health. 2019 Nov;1(7):e334. doi: 10.1016/S2589-7500(19)30160-8. PMID: 33323251.
24. Ullah N, et al. Role of artificial intelligence in healthcare settings: a systematic review. *J Med Artif Intell*. 2025;8:21
25. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019 Oct 29;17(1):195. doi: 10.1186/s12916-019-1426-2. PMID: 31665002; PMCID: PMC6821018.